Eversept Partners LP Reduces Position in Revvity Inc. $RVTY

Eversept Partners LP lessened its stake in shares of Revvity Inc. (NYSE:RVTY) by 58.7% during the 4th quarter, Holdings Channel reports. The firm owned 162,777 shares of the company’s stock after selling 231,534 shares during the quarter. Eversept Partners LP’s holdings in Revvity were worth $15,749,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. CYBER HORNET ETFs LLC purchased a new stake in Revvity during the 2nd quarter worth approximately $32,000. Cromwell Holdings LLC grew its position in Revvity by 141.4% during the 4th quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after purchasing an additional 198 shares during the last quarter. MUFG Securities EMEA plc purchased a new stake in Revvity during the 2nd quarter worth approximately $34,000. Headlands Technologies LLC purchased a new stake in Revvity during the 2nd quarter worth approximately $49,000. Finally, Los Angeles Capital Management LLC purchased a new stake in Revvity during the 4th quarter worth approximately $51,000. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Stock Performance

Shares of NYSE RVTY opened at $97.72 on Thursday. The company has a current ratio of 1.72, a quick ratio of 1.41 and a debt-to-equity ratio of 0.37. The company has a 50 day simple moving average of $95.57 and a two-hundred day simple moving average of $97.62. Revvity Inc. has a 12 month low of $81.22 and a 12 month high of $118.30. The stock has a market cap of $10.90 billion, a price-to-earnings ratio of 46.75, a PEG ratio of 2.21 and a beta of 1.11.

Revvity (NYSE:RVTY) last posted its earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.04. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The firm had revenue of $711.12 million during the quarter, compared to analysts’ expectations of $704.07 million. During the same period in the previous year, the business posted $1.01 EPS. The business’s revenue was up 7.0% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. As a group, analysts predict that Revvity Inc. will post 5.25 earnings per share for the current year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 7th. Investors of record on Friday, July 17th will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Friday, July 17th. Revvity’s payout ratio is currently 13.40%.

Wall Street Analyst Weigh In

Several analysts have commented on RVTY shares. The Goldman Sachs Group decreased their price objective on shares of Revvity from $110.00 to $95.00 and set a “neutral” rating for the company in a research note on Tuesday, April 14th. TD Cowen lifted their price objective on shares of Revvity from $115.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Barclays lifted their price objective on shares of Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. JPMorgan Chase & Co. decreased their price objective on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Finally, Wolfe Research started coverage on shares of Revvity in a research note on Tuesday, June 2nd. They set a “peer perform” rating for the company. Four equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Revvity has a consensus rating of “Hold” and a consensus target price of $107.73.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.